• Explore /
  • Poster
  • / Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.

Abstract Poster

Authors

Heather McArthur

Heather L. McArthur

University of Texas Southwestern Medical Center, Dallas, TX

Heather L. McArthur , Jorge Henrique S. Leal , David B. Page , Christina DiLauro Abaya , Reva K Basho , Michelle Phillips , David Chan , Hugo Hool , Dorothy J. Park , Mary El-Masry , Philomena McAndrew , Swati Sikaria , Laura Spring , Aditya Bardia , Mourad Tighiouart , Farnaz Dadmanesh , Armando E. Giuliano , Stephen Lawrence Shiao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT03747120

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS624)

DOI

10.1200/JCO.2022.40.16_suppl.TPS624

Abstract #

TPS624

Poster Bd #

386b

Abstract Disclosures

Similar Posters

First Author: Heather L. McArthur

First Author: Sayeh Moazami Lavasani

First Author: Nicholas Patrick McAndrew

First Author: Kay T Yeung